Literature DB >> 3029229

Lucigenin chemiluminescence in the assessment of neutrophil superoxide production.

H Gyllenhammar.   

Abstract

Lucigenin-amplified chemiluminescence (LUCL) was induced by .O2- (from the xanthine/xanthine-oxidase reaction) but not, as with luminol-augmented CL (LCL), by myeloperoxidase (MPO) and only weakly by H2O2 or the H2O2-MPO-Cl- system. Neutrophil LUCL induced by fMet-Leu-Phe (fMLP) was dose-dependently inhibited by scavengers of .O2- but not by NaN3, catalase, mannitol or taurine. Response patterns of several soluble stimuli (leukotriene B4 (LTB4), platelet-activating factor (PAF), fMLP, A23187 and phorbol-myristate-acetate (PMA)) were assessed with LUCL. PMA-induced LUCL was protracted, A23187 showed intermediary kinetics whereas fMLP and PAF both showed rapid peak responses at 30-50 s. However, LTB4 was the most rapid initiator of LUCL (7-12 s). The kinetics of fMLP- or PMA-induced neutrophil .O2- production, assessed with the cytochrome C reduction method, correlated well with LUCL. Thus it is suggested that LUCL provides a specific method for studying the kinetic properties of neutrophil .O2- production where stimulus-specific response patterns can be distinguished.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029229     DOI: 10.1016/0022-1759(87)90461-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  55 in total

1.  Activation of neutral sphingomyelinase in human neutrophils by polyunsaturated fatty acids.

Authors:  B S Robinson; C S Hii; A Poulos; A Ferrante
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

2.  Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils.

Authors:  A Ahlin; G Lärfars; G Elinder; J Palmblad; H Gyllenhammar
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Modulation of macrophage activity by proteolytic enzymes. Differential regulation of IL-6 and reactive oxygen intermediates (ROIs) synthesis as a possible homeostatic mechanism in the control of inflammation.

Authors:  K Bryniarski; K Maresz; M Szczepanik; M Ptak; W Ptak
Journal:  Inflammation       Date:  2003-12       Impact factor: 4.092

4.  Dehydroepiandrosterone sulfate directly activates protein kinase C-beta to increase human neutrophil superoxide generation.

Authors:  David J Radford; Keqing Wang; Joanne C McNelis; Angela E Taylor; Georg Hechenberger; Johann Hofmann; Hema Chahal; Wiebke Arlt; Janet M Lord
Journal:  Mol Endocrinol       Date:  2010-02-19

5.  Effect of 22-32 carbon n-3 polyunsaturated fatty acids on superoxide production in human neutrophils: synergism of docosahexaenoic acid with f-met-leu-phe and phorbol ester.

Authors:  A Poulos; B S Robinson; A Ferrante; D P Harvey; S J Hardy; A W Murray
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

6.  Determination of oxygen radical production in spondyloarthropathies by whole blood chemiluminescence.

Authors:  M Ristola; M Leirisalo-Repo; H Repo
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

7.  Modulation of neutrophil superoxide response and intracellular diacylglyceride levels by the bacterial pigment pyocyanin.

Authors:  M Muller; T C Sorrell
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Pharmacological comparison of LTB(4)-induced NADPH oxidase activation in adherent and non-adherent guinea-pig eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; M A Lindsay
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Effect of ingested pentoxifylline on neutrophil superoxide anion production.

Authors:  S P Crouch; J Fletcher
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Activation of phospholipase A2 in human neutrophils by polyunsaturated fatty acids and its role in stimulation of superoxide production.

Authors:  B S Robinson; C S Hii; A Ferrante
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.